UniQuest & PMI collaborate to develop non-addictive pain killers

Date: 2018-01-31   Author: Saipriya Iyer  Category: #industry

UniQuest & PMI collaborate to develop non-addictive pain killers

UniQuest Private Limited, a commercialization unit of the University of Queensland, has apparently signed on a research & option pact with PrevCeutical Medical Incorporation (PMI). Incidentally, PMI, a Canada based biomedical firm, has been a part of this agreement for carrying out research on non-addictive analgesics.

UniQuest plausibly aims to promote the use of peptide disulphide linker technology for developing non-addictive pain killers. According to the CEO of UniQuest, the university is planning to develop a drug other than opioids to avoid pain and use it as a suitable alternative for codeine. Researchers claim that the efforts to introduce alternative methods of pain treatment will certainly help in addressing the global opioid drug overdose issues.

As per reports, the Australian government has decided to prohibit the sale of over-the-counter analgesics with codeine as one of its ingredients from 1st February this year. The new legislation may, in all likelihood, boost the research for developing non-addictive analgesics in the ensuing years. One of the research scientists at the University of Queensland has even gone on record to state that UniQuest had signed four agreements with PMI over the past few months. He further claimed that the joint research to develop non-addictive pain-killing drugs is inclusive of peptide synthesis & testing for their pain killing activity, in addition to its pharmacological & pharmacokinetic assessment in chronic medical conditions.

It has been quoted that earlier in April 2017, UniQuest and PMI had agreed to develop stable peptides for boosting immune system. Sources cite that in the same month both the firms had jointly declared of creating a soluble gel that can transport cannabinoids to the brain through nasal cavity. In the third agreement taking place between the two firms in July last year, it has apparently been reported that they would conduct a joint research program as well, to develop a gene therapy for effectively treating obesity & diabetes.



About Author


Saipriya Iyer linkdin-boxtwitter

Saipriya Iyer

Saipriya Iyer currently works as a content developer for AlgosOnline. A computer engineer by profession, she ventured into the field of writing for the love of playing with words. Having had a previous experience of 3 years under her belt, she has dabbled with website...

Read More

Post Recommendents

Innovations in surveillance system—a growth enabler in air traffic management

Author: Saipriya Iyer

Transforming air traffic management into a more interoperable, automated, modular and scalable system will potentially reap rewards from developments in virtualization and digital technologies. Seamless high-performing...


Stents industry to witness robust technological innovations with ongoing R&D activities

Author: Pankaj Singh

One of the fastest emerging verticals within the healthcare and medical devices space, the global stents market is set to witness numerous interesting trends in the coming years. Ongoing research and development in the...


Amazon India launches ‘Select’ program to assist emerging brands

Author: Shikha Sinha

E-commerce giant Amazon has reportedly started a new program called ‘Select’ in India. As per trusted sources, the program will enable emerging brands in the country to get access to a suite of brand buildi...